0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40

OX40

Brief Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:ATC35 Antigen,OX40 Antigen,ACT35,IMD16,OX40,Receptors, OX40,ACT35 antigen,TNFRSF4,CD134,TNF Receptor Superfamily Member 4,TAX Transcriptionally-Activated Glycoprotein 1 Receptor,CD134 Antigen,TXGP1L,Tumor Necrosis Factor Receptor Superfamily, Member 4,Lym
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

OX0-H5252-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).

OX0-H82F7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.1 μg/mL (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
MEDI-6469 MEDI-6469 Phase 2 Clinical Providence Cancer Center, Agonox Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma Details
Vonlerolizumab RG-7888; MOXR-0916; RO-7021608 Phase 1 Clinical Genentech Inc Carcinoma, Transitional Cell; Neoplasms Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
KHK-4083 KHK-4083 Phase 2 Clinical Kyowa Hakko Kirin Co Ltd Abdominal Pain; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Neoplasms Details
GBR-830 GBR-830 Phase 2 Clinical Glenmark Pharmaceuticals Ltd Dermatitis, Atopic Details
INCAGN-1949 INCAGN-1949 Phase 2 Clinical Agenus Inc, Ludwig Institute For Cancer Research Carcinoma, Renal Cell; Urogenital Neoplasms; Neoplasm Metastasis Details
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) YH-002 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours Details
PF-04518600 PF-8600; PF-04518600 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Carcinoma, Renal Cell; Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase 1 Clinical Livzon Pharmaceutical Group Inc Neoplasms Details
GSK3174998 GSK3174998; GSK 3174998; GSK-3174998 Phase 2 Clinical Glaxosmithkline Plc Head and Neck Neoplasms; Neoplasms; Multiple Myeloma Details
mRNA-2416 mRNA-2416; OX40L mRNA - Moderna Therpeutics Phase 2 Clinical Moderna Therapeutics Ovarian Neoplasms; Solid tumours; Lymphoma Details
Cudarolimab IBI-101 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
BAT-6026 BAT-6026 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd Solid tumours Details
BGB-A445 BGB-A445 Phase 1 Clinical Beigene Ltd Solid tumours Details
BMS-986178 BMS-986178 Phase 2 Clinical Bristol-Myers Squibb Company Neoplasms Details
INBRX-106 INBRX-106; ES-102; ES102 Phase 1 Clinical Inhibrx Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop